All articles tagged with #triple negative
Chance Osborne, a 24-year-old BRCA1 carrier, developed triple negative breast cancer two weeks after a clear MRI. The tumor doubled in size within two weeks of discovery. She underwent chemotherapy, surgery, and a hysterectomy, surviving five years. She now advocates for genetic testing and regular circulating tumor DNA monitoring.
A California mom with triple-negative breast cancer underwent the United States’ first robotic single-port nipple-sparing mastectomy outside clinical trials, using a $2 million Da Vinci SP robot named Carol at Sutter Health’s Alta Bates Summit Medical Center. The procedure preserves the nipple and skin through a tiny initial incision and 3D magnified vision, with the surgeon in full control. The FDA has cleared the robot for nipple-sparing mastectomies, signaling broader adoption as more centers train. Pan is now in remission but continues chemotherapy and immunotherapy to prevent recurrence and will need reconstructive surgery, marking a hopeful milestone in cancer care and surgical technology.
A 43-year-old woman from Newcastle discovered a tiny sore on her breast in 2021 that was later diagnosed as stage 3 triple-negative breast cancer; after lumpectomy and chemotherapy, she learned she carries the PALB2 gene mutation and chose a preventive double mastectomy in 2022, highlighting the importance of early symptom checks and ongoing follow-up.
AstraZeneca and Gilead Sciences presented successful trial results for antibody-drug conjugates as new first-line treatments for metastatic triple-negative breast cancer, offering potential options after over a decade without new approvals for this aggressive cancer type.
Misty De La Cruz, a mother battling stage three triple-negative breast cancer with a 20% survival chance, faces not only her health challenges but also the emotional toll on her children, especially after her son's heartbreaking fear of losing her. Her diagnosis, treatment, and genetic mutation highlight the rising incidence of breast cancer among younger women, emphasizing the importance of regular self-exams and early detection.
A new vaccine trial for patients with triple-negative breast cancer has shown promising results, with an 88% survival rate after three years. Conducted by Washington University School of Medicine, the trial involved 18 patients who received a personalized neoantigen DNA vaccine alongside standard care. The vaccine was well-tolerated and stimulated immune responses in most patients, with 16 remaining cancer-free after three years. Although the trial lacked a control group, historical data suggests the vaccine may significantly improve outcomes compared to standard treatments alone. Further randomized controlled trials are underway to confirm these findings.